Stay informed on the latest in arthritis prevention, research, treatment and care with JointHealth™ express, Canada's trusted source for arthritis news. Delivered right to your inbox, this "breaking news" bulletin provides timely updates on key arthritis topics, including disease management, research breakthroughs, and treatment advancements. As the longest-running arthritis news source in Canada, JointHealth™ express provides you expert insights from patients and analysis from arthritis health care professionals to help you on your arthritis journey. Stay connected to the arthritis information that matters most.
Click here to see JointHealth™ express bulletins from 2023 and earlier.
Latest News
Arthritis At Home 276 – Determinants of health inequities and decision-making in juvenile idiopathic arthritis care
Arthritis At Home 275 – Moving more with inflammatory arthritis and strategies for behaviour change
Arthritis At Home 274 – Inflammatory bowel disease and its connection with spondyloarthritis
JointHealth™ insight – May 2025
New blog post from Joint Journeys, life with arthritis by Carrie: RA on the trail
Arthritis At Home 273 – Safety of rituximab, antinuclear antibody testing in lupus, and deprescribing
Update on availability of infliximab biosimilar Inflectra®
The infliximab biosimilar Inflectra® will be discontinued in Canada as of September 30, 2025. This means that patients currently receiving ...
Arthritis At Home 272 – Making artificial intelligence in medicine a reality
Call for patient input on upadacitinib (Rinvoq®) for giant cell arteritis
Canada’s Drug Agency (CDA-AMC) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s ...
Arthritis At Home 271 – Lupus and pregnancy in women in Alberta
Call for patient input on inebilizumab (Uplizna®) for immunoglobulin G4-related disease
Canada’s Drug Agency (CDA-AMC) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s ...
